Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska, Bartosz Malinowski
Format: Artigo
Sprog:Inglês
Udgivet: MDPI AG 2020-03-01
Serier:International Journal of Molecular Sciences
Fag:
vildagliptin
endothelium
inflammation
atherogenesis
pathways
pharmacology
Online adgang:https://www.mdpi.com/1422-0067/21/7/2275
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker